Progress is a pattern assessed over time, alongside tolerability and health goals. Planning for maintenance or stopping should begin before a prescription ends or a target weight is reached.
A trial average is not a personal timetable
STEP 1's widely quoted 14.9% average reduction was measured at 68 weeks with 2.4 mg semaglutide in adults without diabetes. It was not the amount everyone lost, and it was not an early-month target. The placebo group also received lifestyle support. A percentage without those details removes much of the context needed to interpret it.
When setting expectations, ask what the service will assess and at what point. The first useful milestone may be whether the prescribed routine is manageable. Keep outcome discussions specific: weight trend, daily function, symptoms and any health measures the clinician has chosen to follow.
Sources: New England Journal of Medicine: STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity; NICE: Overweight and obesity management: medicines and surgery
Give a plateau a proper description
Instead of reporting only that weight loss has stopped, bring dates and measurements taken in a consistent way. Note dose changes, missed doses, illness, changes in activity and problems with intake. This helps the clinician examine what has happened without assuming that the next step must be a higher dose.
A plateau is a reason to review the plan, not evidence that you should combine medicines, shorten the dosing interval or eat progressively less. Explain how the treatment feels in practice and whether your original goals still make sense. A realistic review may involve clarifying the measurement period before deciding whether to change anything.
Sources: NICE: Overweight and obesity management: medicines and surgery; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics
Know which continuation rule is being discussed
NICE's NHS semaglutide guidance advises considering stopping when less than 5% of initial weight has been lost after six months, and places treatment within a specialist service for a maximum of two years under that recommendation. These are funding and clinical guidance conditions for that pathway. They should not be confused with a universal two-year safety limit for the molecule.
Ask the service which guidance applies to your care, how it measures response and what an approaching end date means. If treatment is private, ask for its review and stopping policy. A clear policy is more useful than discovering a limit at the point of your final order.
Sources: NICE: TA875: Semaglutide for managing overweight and obesity
Discuss what happens after treatment changes
STEP 4 provides evidence that stopping can change the weight trajectory. After an initial semaglutide period, participants continuing treatment lost further weight on average; those switched to placebo regained weight on average. The trial supports discussing maintenance, but it cannot predict exactly what will happen to an individual after stopping.
Agree what support continues, when weight or health measures will be reviewed and how you can return for help. Avoid framing a later increase in weight as a personal failure. The practical issue is whether the management plan still addresses your needs and what options remain available.
Sources: JAMA / PubMed: STEP 4: Continued semaglutide versus placebo for weight loss maintenance; NHS: Overweight and obesity in adults
Make the exit plan practical as well as clinical
If cost may force a change, raise it before the next supply runs out. Ask the prescriber to consider the timing of reviews, alternative care options and any necessary diabetes monitoring. Do not stretch doses or create a taper from pen clicks because an online anecdote describes doing so.
Write down who is responsible for follow-up after the prescribing service finishes. Keep a summary of medicine, dose history and relevant problems to share with another clinician. A planned handover should leave you knowing the next contact point, rather than simply receiving a last parcel.
Sources: General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online; Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: patient information leaflet; NHS England: Weight management injections: NHS England patient information
Questions, answered.
Does reaching a plateau mean the medicine has failed?
It needs a review in context. A single observation does not establish why the trend changed or what treatment decision is appropriate.
Sources: NICE: Overweight and obesity management: medicines and surgery
Will everyone regain the same amount after stopping?
No. Withdrawal studies report group outcomes. They support planning follow-up, not predicting a fixed amount of regain for each person.
Sources: JAMA / PubMed: STEP 4: Continued semaglutide versus placebo for weight loss maintenance
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · Accessed 19 November 2026
- Overweight and obesity management: medicines and surgeryNICE · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- TA875: Semaglutide for managing overweight and obesityNICE · Accessed 19 November 2026
- STEP 4: Continued semaglutide versus placebo for weight loss maintenanceJAMA / PubMed · Accessed 19 November 2026
- Overweight and obesity in adultsNHS · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
- Wegovy FlexTouch: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Weight management injections: NHS England patient informationNHS England · Accessed 19 November 2026
